Genmab A/S operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other
miscellaneous service companies in Europe:
Bachem Holding AG
sales of 261.61 million Swiss Francs [US$260.05 million]
of which 88%
was Active Pharmaceutical Ingredients),
(2.33 billion Swedish Kronor [US$256.97 million]
of which 60%
was LabTech), and
Clinigen Group PLC
based in the United Kingdom
(£302.30 million [US$392.09 million]
of which 36%
was Clinical Trial services).
Genmab A/S reported sales of 2.37 billion Danish Kroner (US$359.50 million)
December of 2017.
increase of 30.2%
versus 2016, when the company's sales were 1.82 billion Danish Kroner.
Sales at Genmab A/S have increased during each of the previous five years
(and since 2012, sales have increased a total of 388%).